文献速递血液净化与透析

HEMO研究:对甲酚硫酸盐与吲哚硫酸盐未与心血管结局相关

Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes.
PubMed 文献 · Kidney Int · 2017-07-21

HEMO研究纳入1,273例血液透析患者,分析透析前总对甲酚硫酸盐、吲哚硫酸盐、苯乙酰谷氨酰胺和马尿酸盐与心脏死亡、心源性猝死及首次心血管事件的关系。总体无关联,但低白蛋白(<3.6 g/dl)亚组中对甲酚硫酸盐加倍与心脏死亡风险升高12%、心源性猝死风险升高22%相关。

要点

  • 透析前对甲酚硫酸盐、吲哚硫酸盐等尿毒症溶质总体与心血管结局无关联。
  • 血清白蛋白<3.6 g/dl者中对甲酚硫酸盐加倍与心脏死亡及心源性猝死风险升高相关。
  • 常规临床和实验室数据仅解释溶质水平变异的不到22%。

核心结论

  • 在HEMO研究血液透析患者中,对甲酚硫酸盐、吲哚硫酸盐、马尿酸盐和苯乙酰谷氨酰胺与心血管结局无总体关联。
  • 低血清白蛋白患者中对甲酚硫酸盐和吲哚硫酸盐呈现毒性趋势。

研究设计与样本

  • HEMO研究的事后分析,纳入1,273例血液透析参与者。
  • 检测透析前总对甲酚硫酸盐、吲哚硫酸盐、苯乙酰谷氨酰胺和马尿酸盐水平。
  • 结局为心脏死亡、心源性猝死和首次心血管事件,并调整人口学、临床和实验室混杂因素。

主要发现

  • 患者平均年龄58岁,63%为黑人,42%为男性。
  • 总体分析中溶质与结局无关联。
  • 血清白蛋白<3.6 g/dl者中对甲酚硫酸盐加倍与心脏死亡风险升高12%相关(HR 1.12;95%CI 0.98-1.27)。
  • 血清白蛋白<3.6 g/dl者中对甲酚硫酸盐加倍与心源性猝死风险升高22%相关(HR 1.22;95%CI 1.06-1.41)。
  • 吲哚硫酸盐也呈现相似趋势,试验干预未改变溶质与结局的关联。

关键数值与推荐

  • 低血清白蛋白定义为<3.6 g/dl。
  • 对甲酚硫酸盐加倍与心脏死亡:HR 1.12(95%CI 0.98-1.27)。
  • 对甲酚硫酸盐加倍与心源性猝死:HR 1.22(95%CI 1.06-1.41)。
  • 常规临床和实验室数据解释溶质水平变异<22%。

临床怎么用

  • 对于血清白蛋白<3.6 g/dl的血液透析患者,可关注对甲酚硫酸盐和吲哚硫酸盐水平以评估心血管风险趋势。
  • 总体血透人群中常规检测这些尿毒症溶质对心血管风险分层的价值有限。

局限性

  • 为HEMO研究的事后分析,亚组分析结果需谨慎解读。
  • 低白蛋白亚组中对甲酚硫酸盐与心脏死亡的关联95%CI包含1。
  • 常规临床和实验室数据仅解释溶质水平变异的不到22%,提示存在未测量因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular disease, the leading cause of mortality in hemodialysis patients, is not fully explained by traditional risk factors. To help define non-traditional risk factors, we determined the association of predialysis total p-cresol sulfate, indoxyl sulfate, phenylacetylglutamine, and hippurate with cardiac death, sudden cardiac death, and first cardiovascular event in the 1,273 participants of the HEMO Study. The results were adjusted for potential demographic, clinical, and laboratory confounders. The mean age of the patients was 58 years, 63% were Black and 42% were male. Overall, there was no association between the solutes and outcomes. However, in sub-group analyses, among patients with lower serum albumin (under 3.6 g/dl), a twofold higher p-cresol sulfate was significantly associated with a 12% higher risk of cardiac death (hazard ratio 1.12; 95% confidence interval, 0.98-1.27) and 22% higher risk of sudden cardiac death (1.22, 1.06-1.41). Similar trends were also noted with indoxyl sulfate. Trial interventions did not modify the association between these solutes and outcomes. Routine clinical and lab data explained less than 22% of the variability in solute levels. Thus, in prevalent hemodialysis patients participating in a large U.S. hemodialysis trial, uremic solutes p-cresol sulfate, indoxyl sulfate, hippurate, and phenylacetylglutamine were not associated with cardiovascular outcomes. However, there were trends of toxicity among patients with lower serum albumin.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Shafi T, Sirich TL, Meyer TW, et al. Results of the HEMO Study suggest that p-cresol sulfate and indoxyl sulfate are not associated with cardiovascular outcomes. Kidney Int. 2017. PMID: 28739139. doi:10.1016/j.kint.2017.05.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。